Article info

Download PDFPDF
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study

Authors

  1. Correspondence to Dr Zachary S Wallace, Clinical Epidemiology Program, Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA 02114, USA; zswallace{at}partners.org
View Full Text

Citation

McDermott G, Fu X, Cook C, et al
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study

Publication history

  • Received March 7, 2022
  • Accepted May 24, 2022
  • First published June 13, 2022.
Online issue publication 
September 12, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.